CMA - Infertility, IVF, RPL

Chromosomal Microarray (CMA) - Infertility, IVF, and Recurrent Pregnancy Loss (RPL)

Navigating the challenges of infertility, IVF, and recurrent pregnancy loss (RPL) can be emotionally and physically taxing. For many couples, understanding the genetic underpinnings of these issues is a crucial step towards effective management and successful outcomes. Chromosomal Microarray (CMA) has emerged as a powerful tool in this realm, offering a detailed genomic analysis that can uncover genetic causes often missed by traditional methods. This high-resolution technique provides invaluable insights into chromosomal abnormalities, helping to tailor interventions and increase the chances of a successful pregnancy.

Chromosomal Microarray (CMA) is an advanced genetic testing method that analyzes the entire genome to detect submicroscopic chromosomal deletions and duplications known as copy number variants (CNVs). Unlike traditional karyotyping, which examines chromosomes under a microscope, CMA uses sophisticated microarray technology to provide a higher resolution view of the genome. This allows for the detection of smaller genetic variations that might be associated with various genetic disorders.

For individuals facing infertility or undergoing IVF treatments, CMA can identify genetic factors that contribute to these challenges. It can detect abnormalities such as numerical sex chromosome abnormalities, Y microdeletions, and other genetic conditions that affect reproductive health. Additionally, CMA plays a crucial role in assessing genetic causes of recurrent pregnancy loss, providing insights into potential genetic factors influencing miscarriage risk.

Clinical Utility

  1. Infertility: CMA helps identify chromosomal abnormalities that may be contributing to infertility. By detecting genetic factors that could impact reproductive health, CMA enables clinicians to develop targeted treatment plans and interventions.

  2. IVF: For couples undergoing in vitro fertilization, CMA offers critical information for embryo selection. By analyzing the genetic profile of embryos, CMA can guide the selection of embryos with the best chances of successful implantation and development.

  3. Recurrent Pregnancy Loss (RPL): Recurrent pregnancy loss is defined as three or more consecutive miscarriages before 20 weeks of gestation. CMA is an effective tool for identifying genetic abnormalities that may be causing these losses. It provides valuable information for counseling and management of future pregnancies, helping to estimate recurrence risk and make informed decisions.

  4. Genetic Counseling: CMA results inform genetic counseling sessions, offering a clearer understanding of genetic risks and guiding families in their decision-making process regarding future pregnancies and reproductive options.

When to Consider CMA

  1. Infertility: Couples who have been unable to conceive for over a year, or those with a history of unsuccessful pregnancies, may benefit from CMA. It is especially recommended when there is a known issue with sperm count or ovarian function.

  2. IVF: Prior to starting IVF treatment, CMA can be used to screen for chromosomal abnormalities in prospective embryos. This helps in selecting embryos with a lower risk of genetic disorders, improving the chances of a successful pregnancy.

  3. Recurrent Pregnancy Loss: For couples experiencing recurrent pregnancy loss, CMA is recommended to identify any underlying genetic causes. It helps in understanding the reasons behind multiple miscarriages and provides insights into managing future pregnancies.

  4. Advanced Maternal Age: Women of advanced maternal age undergoing IVF or facing recurrent pregnancy loss should consider CMA to assess any genetic risks associated with age-related chromosomal abnormalities.

  5. Family History of Genetic Diseases: Couples with a family history of genetic disorders or abnormalities should consider CMA to evaluate their genetic risk and make informed decisions about family planning.

MapmyGenome Offerings

MapmyGenome provides comprehensive CMA services using cutting-edge technology to deliver accurate and detailed genetic insights. Our offerings include:

Test specification

Technique

Platform

Variant types

TAT

Sample Requirements

Microarray

Illumina 700K gene chip

CNV

3 -4  weeks

EDTA Blood or Extracted DNA samples (1µg - 2µg), POC  100-200g in PBS Solution, (Mother Blood for MCC assay), CVS Sample/Amniotic Fluid/Cultured Cells - Cell Pellet in 1.5mL tube

 

Learn more:

Read: Unlocking the Secrets of CMA: A Game-Changer for Infertility, IVF, and RPL

Listen: CMA Insights for Overcoming Infertility, IVF Challenges, and RPL

Watch: How CMA Revolutionizes Care for Infertility, IVF, and Recurrent Pregnancy Loss

FAQs




What is Chromosomal Microarray Analysis (CMA)?

CMA is a genetic test that detects small chromosomal changes, such as deletions or duplications, that may not be visible with traditional karyotyping.

How does CMA benefit infertility/IVF/RPL cases?

How does CMA impact the IVF process?

What kind of genetic abnormalities can CMA detect?

How is a CMA test conducted?

What is the turnaround time for CMA results?

Are there any risks associated with CMA?

How does CMA differ from karyotyping?

What do the results of a CMA test indicate?

Can both partners undergo CMA testing?

What steps follow if CMA detects an abnormality?